Zhongzhi Pharmaceutical Holdings Limited provided unaudited consolidated earnings guidance for the year ended 31 December 2024. For the period, the group is expected a decrease in net profit of around 45% for the year ended 31 December 2024 are expected as compared to those for the year ended 31 December 2023. The expected decrease in net profit is mainly attributable to: (i) a decrease in gross profit margin due to structural changes in the products sold; (ii) an increase in investment costs through online channels and offline advertising expenses.